Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov;110(6):770-5.
doi: 10.1002/jso.23702. Epub 2014 Jul 3.

Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review

Affiliations

Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review

Brett A Byers et al. J Surg Oncol. 2014 Nov.

Abstract

Background: Several phase II studies have assessed intra-lesional interleukin-2 (IL-2) for the treatment of in-transit melanoma. This systematic review addresses the efficacy and side effect profile of IL-2.

Methods: MEDLINE, EMBASE, Cochrane Library, and Google Scholar databases were searched from 1980 to 2012 for studies evaluating the clinical response to IL-2 for in-transit melanoma. Titles and abstracts were screened by two independent researchers for suitability using predetermined inclusion and exclusion criteria. A modified quality assessment tool for observational studies was used. Data were pooled and analyzed to determine lesion and patient response rates.

Results: Forty-nine studies were identified. Forty-three did not meet inclusion criteria, leaving six observational trials. Heterogeneity was seen in IL-2 dosage and treatment interval. Response rate was variable as well. Overall, 2,182 lesions and 140 patients were treated in these six studies. Pooling the lesions, complete response was seen in 78%. Pooling subjects, 50% achieved a complete response. Treatment was generally well tolerated, with localized pain and swelling, and mild flu-like symptoms. There were only three grade 3 adverse events reported, including rigors, headache, and fever with arthralgia.

Conclusions: Intra-lesional IL-2 safely and effectively provides locoregional control of in-transit melanoma.

Keywords: in-transit melanoma; interleukin-2; intra-lesional; melanoma.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources